GSK plc (NYSE:GSK) Stake Boosted by Robinson Value Management Ltd.

Robinson Value Management Ltd. increased its position in shares of GSK plc (NYSE:GSK) by 2.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,101 shares of the pharmaceutical company’s stock after acquiring an additional 1,494 shares during the period. Robinson Value Management Ltd.’s holdings in GSK were worth $1,931,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Eastern Bank bought a new stake in shares of GSK in the 3rd quarter valued at approximately $26,000. Crews Bank & Trust acquired a new stake in GSK in the fourth quarter valued at approximately $26,000. ST Germain D J Co. Inc. grew its position in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 522 shares in the last quarter. Sunbelt Securities Inc. increased its stake in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the last quarter. Finally, Concord Wealth Partners raised its holdings in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 547 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and lowered their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Six investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Stock Down 1.0 %

GSK stock opened at $36.03 on Friday. The firm has a market cap of $74.68 billion, a price-to-earnings ratio of 22.66, a P/E/G ratio of 1.42 and a beta of 0.64. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.53. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The firm has a fifty day moving average price of $34.25 and a two-hundred day moving average price of $37.57.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, analysts forecast that GSK plc will post 4.07 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.36%. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is currently 93.08%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.